Related Experiment Video

Updated: Apr 29, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Resistance to Raf inhibition in cancer

H Eirik Haarberg, Keiran S M Smalley

    Drug Discovery Today. Technologies
    |May 23, 2014
    PubMed

    Insights

    Small molecule BRAF inhibitors transformed advanced melanoma treatment, but drug resistance remains a challenge. This review explores combination therapies to overcome resistance mechanisms like MAPK and PI3K/AKT pathway reactivation.

    Area of Science:

    • Oncology
    • Pharmacology
    • Dermatology

    Background:

    • Small molecule BRAF inhibitors have significantly advanced advanced melanoma treatment.
    • Acquired drug resistance is a major clinical challenge, limiting long-term patient survival.
    • Key resistance mechanisms involve MAPK pathway reactivation and PI3K/AKT signaling.

    Purpose of the Study:

    • To review current combination therapeutic strategies for managing acquired BRAF inhibitor resistance in melanoma.
    • To highlight emerging treatment approaches for overcoming common resistance mechanisms.

    Main Methods:

    • Literature review of preclinical and clinical studies.
    • Analysis of combination therapies targeting BRAF inhibitor resistance pathways.
    • Synthesis of data on therapeutic efficacy and resistance modulation.

    Main Results:

    • Several combination strategies are under investigation to counteract melanoma drug resistance.
    • Targeting MAPK and PI3K/AKT pathways concurrently shows promise.
    • Evaluating novel therapeutic combinations is crucial for improving patient outcomes.

    Conclusions:

    • Combination therapies represent a promising strategy to overcome acquired resistance to BRAF inhibitors in melanoma.
    • Further research and clinical evaluation are needed to establish optimal combination regimens.
    • Addressing resistance mechanisms is essential for durable responses in advanced melanoma patients.

    More Related Videos

    Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

    Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

    Published on: March 1, 2024

    1.9K
    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    7.6K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    2.6K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.6K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    5.7K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    3.8K
    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a...
    5.7K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    4.8K